tiprankstipranks
Pfizer (PFE)
NYSE:PFE
US Market
PFE
Pfizer
RESEARCH TOOLSreports
Want to see PFE full AI Analyst Report?

Pfizer (PFE) Stock Forecast & Price Target

36,203 Followers
See the Price Targets and Ratings of:

PFE Analyst Ratings

Moderate Buy
23Ratings
Moderate Buy
9 Buy
12 Hold
2 Sell
Based on 23 analysts giving stock ratings to
Pfizer
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PFE Stock 12 Month Forecast

Average Price Target

$29.50
▲(7.03% Upside)
Based on 23 Wall Street analysts offering 12 month price targets for Pfizer in the last 3 months. The average price target is $29.50 with a high forecast of $36.00 and a low forecast of $25.00. The average price target represents a 7.03% change from the last price of $27.56.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","25":"$25","29":"$29","33":"$33","37":"$37"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.49809523809524,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,25,29,33,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.55,29.123076923076923,29.696153846153848,30.26923076923077,30.842307692307692,31.415384615384617,31.98846153846154,32.56153846153846,33.13461538461539,33.707692307692305,34.28076923076923,34.853846153846156,35.426923076923075,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.55,28.622930402930404,28.695860805860807,28.76879120879121,28.841721611721614,28.914652014652017,28.98758241758242,29.06051282051282,29.133443223443223,29.206373626373626,29.27930402930403,29.352234432234432,29.425164835164836,{"y":29.49809523809524,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.55,28.276923076923076,28.003846153846155,27.73076923076923,27.45769230769231,27.184615384615384,26.911538461538463,26.638461538461538,26.365384615384617,26.092307692307692,25.81923076923077,25.546153846153846,25.273076923076925,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.879,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.31,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.289,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 55, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.79,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.703,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.93,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.298,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.824,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.853,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.489,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.66,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.26,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.55,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$36.00Average Price Target$29.50Lowest Price Target$25.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on PFE
Courtney Breen
Bernstein
Bernstein
$30
Hold
8.85%
Upside
Reiterated
04/21/26
Pfizer (PFE) Receives a Hold from Bernstein
Barclays Analyst forecast on PFE
Emily Field
Barclays
Barclays
$25
Sell
-9.29%
Downside
Reiterated
04/21/26
Barclays Remains a Sell on Pfizer (PFE)
RBC Capital Analyst forecast on PFE
Trung Huynh
RBC Capital
RBC Capital
$25
Sell
-9.29%
Downside
Reiterated
04/20/26
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS), Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE)
Goldman Sachs Analyst forecast on PFE
Asad Haider
Goldman Sachs
Goldman Sachs
$26→$33
Buy
19.74%
Upside
Upgraded
04/16/26
Analysts Conflicted on These Healthcare Names: CareDx (NASDAQ: CDNA) and Pfizer (NYSE: PFE)
Scotiabank Analyst forecast on PFE
Louise Chen
Scotiabank
Scotiabank
$30
Buy
8.85%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL) and Pfizer (NYSE: PFE)
Wells Fargo Analyst forecast on PFE
Mohit Bansal
Wells Fargo
Wells Fargo
$28
Hold
1.60%
Upside
Assigned
04/13/26
Wells Fargo Releases a Hold Rating on Pfizer (PFE)
UBS Analyst forecast on PFE
Michael Yee
UBS
UBS
$25→$27
Hold
-2.03%
Downside
Assigned
04/13/26
Pfizer price target raised to $27 from $25 at UBSPfizer price target raised to $27 from $25 at UBS
Guggenheim Analyst forecast on PFE
Vamil Divan
Guggenheim
Guggenheim
$36
Buy
30.62%
Upside
Reiterated
04/12/26
Analysts Are Bullish on Top Healthcare Stocks: InflaRx (IFRX), Pfizer (PFE)
Morgan Stanley Analyst forecast on PFE
Terence Flynn
Morgan Stanley
Morgan Stanley
$27→$28
Hold
1.60%
Upside
Assigned
04/10/26
Pfizer (PFE) Gets a Hold from Morgan Stanley
J.P. Morgan Analyst forecast on PFE
Chris Schott
J.P. Morgan
J.P. Morgan
$30
Hold
8.85%
Upside
Reiterated
04/10/26
Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE) and Sanofi (Other OTC: SNYNF)
Bank of America Securities Analyst forecast on PFE
Jason Gerberry
Bank of America Securities
Bank of America Securities
$27→$26
Hold
-5.66%
Downside
Reiterated
04/09/26
Pfizer price target lowered to $26 from $27 at BofAPfizer price target lowered to $26 from $27 at BofA
Erste Group Analyst forecast on PFE
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
04/02/26
Erste Group Remains a Hold on Pfizer (PFE)
Jefferies Analyst forecast on PFE
Akash Tewari
Jefferies
Jefferies
$34
Buy
23.37%
Upside
Reiterated
03/24/26
Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE) and Idexx Laboratories (NASDAQ: IDXX)
Citi Analyst forecast on PFE
Geoff Meacham
Citi
Citi
$26
Hold
-5.66%
Downside
Reiterated
03/24/26
Citi Remains a Hold on Pfizer (PFE)
TD Cowen Analyst forecast on PFE
Steve Scala
TD Cowen
TD Cowen
$30
Hold
8.85%
Upside
Reiterated
03/24/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Pfizer (NYSE: PFE) and Wave Life Sciences (NASDAQ: WVE)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on PFE
Courtney Breen
Bernstein
Bernstein
$30
Hold
8.85%
Upside
Reiterated
04/21/26
Pfizer (PFE) Receives a Hold from Bernstein
Barclays Analyst forecast on PFE
Emily Field
Barclays
Barclays
$25
Sell
-9.29%
Downside
Reiterated
04/21/26
Barclays Remains a Sell on Pfizer (PFE)
RBC Capital Analyst forecast on PFE
Trung Huynh
RBC Capital
RBC Capital
$25
Sell
-9.29%
Downside
Reiterated
04/20/26
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS), Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE)
Goldman Sachs Analyst forecast on PFE
Asad Haider
Goldman Sachs
Goldman Sachs
$26→$33
Buy
19.74%
Upside
Upgraded
04/16/26
Analysts Conflicted on These Healthcare Names: CareDx (NASDAQ: CDNA) and Pfizer (NYSE: PFE)
Scotiabank Analyst forecast on PFE
Louise Chen
Scotiabank
Scotiabank
$30
Buy
8.85%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL) and Pfizer (NYSE: PFE)
Wells Fargo Analyst forecast on PFE
Mohit Bansal
Wells Fargo
Wells Fargo
$28
Hold
1.60%
Upside
Assigned
04/13/26
Wells Fargo Releases a Hold Rating on Pfizer (PFE)
UBS Analyst forecast on PFE
Michael Yee
UBS
UBS
$25→$27
Hold
-2.03%
Downside
Assigned
04/13/26
Pfizer price target raised to $27 from $25 at UBSPfizer price target raised to $27 from $25 at UBS
Guggenheim Analyst forecast on PFE
Vamil Divan
Guggenheim
Guggenheim
$36
Buy
30.62%
Upside
Reiterated
04/12/26
Analysts Are Bullish on Top Healthcare Stocks: InflaRx (IFRX), Pfizer (PFE)
Morgan Stanley Analyst forecast on PFE
Terence Flynn
Morgan Stanley
Morgan Stanley
$27→$28
Hold
1.60%
Upside
Assigned
04/10/26
Pfizer (PFE) Gets a Hold from Morgan Stanley
J.P. Morgan Analyst forecast on PFE
Chris Schott
J.P. Morgan
J.P. Morgan
$30
Hold
8.85%
Upside
Reiterated
04/10/26
Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE) and Sanofi (Other OTC: SNYNF)
Bank of America Securities Analyst forecast on PFE
Jason Gerberry
Bank of America Securities
Bank of America Securities
$27→$26
Hold
-5.66%
Downside
Reiterated
04/09/26
Pfizer price target lowered to $26 from $27 at BofAPfizer price target lowered to $26 from $27 at BofA
Erste Group Analyst forecast on PFE
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
04/02/26
Erste Group Remains a Hold on Pfizer (PFE)
Jefferies Analyst forecast on PFE
Akash Tewari
Jefferies
Jefferies
$34
Buy
23.37%
Upside
Reiterated
03/24/26
Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE) and Idexx Laboratories (NASDAQ: IDXX)
Citi Analyst forecast on PFE
Geoff Meacham
Citi
Citi
$26
Hold
-5.66%
Downside
Reiterated
03/24/26
Citi Remains a Hold on Pfizer (PFE)
TD Cowen Analyst forecast on PFE
Steve Scala
TD Cowen
TD Cowen
$30
Hold
8.85%
Upside
Reiterated
03/24/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Pfizer (NYSE: PFE) and Wave Life Sciences (NASDAQ: WVE)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pfizer

3 Months
xxx
Success Rate
28/35 ratings generated profit
80%
Average Return
+3.81%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +3.81% per trade.
1 Year
Vamil DivanGuggenheim
Success Rate
30/35 ratings generated profit
86%
Average Return
+7.87%
Copying Vamil Divan's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +7.87% per trade.
2 Years
xxx
Success Rate
19/21 ratings generated profit
90%
Average Return
+11.36%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 90.48% of your transactions generating a profit, with an average return of +11.36% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PFE Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
16
12
13
13
15
Hold
34
33
33
30
28
Sell
0
0
2
2
5
Strong Sell
0
0
0
0
0
total
50
45
48
45
48
In the current month, PFE has received 15 Buy Ratings, 28 Hold Ratings, and 5 Sell Ratings. PFE average Analyst price target in the past 3 months is 29.50.
Each month's total comprises the sum of three months' worth of ratings.

PFE Financial Forecast

PFE Earnings Forecast

Next quarter’s earnings estimate for PFE is $0.72 with a range of $0.56 to $0.81. The previous quarter’s EPS was $0.66. PFE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PFE has Performed in-line its overall industry.
Next quarter’s earnings estimate for PFE is $0.72 with a range of $0.56 to $0.81. The previous quarter’s EPS was $0.66. PFE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PFE has Performed in-line its overall industry.

PFE Sales Forecast

Next quarter’s sales forecast for PFE is $13.81B with a range of $13.26B to $14.21B. The previous quarter’s sales results were $17.56B. PFE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PFE has Performed in-line its overall industry.
Next quarter’s sales forecast for PFE is $13.81B with a range of $13.26B to $14.21B. The previous quarter’s sales results were $17.56B. PFE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PFE has Performed in-line its overall industry.

PFE Stock Forecast FAQ

What is PFE’s average 12-month price target, according to analysts?
Based on analyst ratings, Pfizer’s 12-month average price target is 29.50.
    What is PFE’s upside potential, based on the analysts’ average price target?
    Pfizer has 7.03% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PFE a Buy, Sell or Hold?
          Pfizer has a consensus rating of Moderate Buy which is based on 9 buy ratings, 12 hold ratings and 2 sell ratings.
            What is Pfizer’s price target?
            The average price target for Pfizer is 29.50. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $36.00 ,the lowest forecast is $25.00. The average price target represents 7.03% Increase from the current price of $27.56.
              What do analysts say about Pfizer?
              Pfizer’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.
                How can I buy shares of PFE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.